← Ahmad Masri

Papers by Ahmad Masri

Page 1 · newest first

1. Cardiomyocyte-Derived Cell-Free DNA in Hypertrophic Cardiomyopathy2026
2. Patient-Reported Benefits of Acoramidis Across Genotypes in Transthyretin Amyloid Cardiomyopathy: KCCQ and EQ-5D-5L Outcomes From ATTRibute-CMJournal of Cardiac Failure · 2026
3. Aficamten is associated with improvements in cardiac mechanics in obstructive hypertrophic cardiomyopathy: Results from FOREST-HCMProgress in Cardiovascular Diseases · 2026
4. Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trialNature Medicine · 2026
5. Comparative efficacy and safety of acoramidis versus tafamidis in patients with transthyretin amyloid cardiomyopathy: an anchored matching-adjusted indirect comparisonEuropean Heart Journal Open · 2026
6. EARTH-HCM: A Real-World Tool to Visualize the Burden of Hypertrophic Cardiomyopathy in the United StatesESC Heart Failure · 2026
7. HF STATS 2026: An Updated Report on Heart Failure Epidemiology and Outcomes from the Heart Failure Society of AmericaJournal of Cardiac Failure · 2026
8. In Participants Treated With Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR LevelsJournal of the American College of Cardiology · 2025
9. Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE‐CM, a Randomized Controlled TrialJournal of the American Heart Association · 2026
10. 124Iodine Evuzamitide Positron Emission Tomography in Patients with Established or Suspected Cardiac AmyloidosisJACC. Cardiovascular imaging · 2026
11. Gene Silencer Therapy in Transthyretin Amyloid CardiomyopathyJAMA · 2026
12. 124 I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac AmyloidosisJAMA · 2026
13. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM TrialCirculation · 2024
14. Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic CardiomyopathyCirculation · 2026
15. Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic CardiomyopathyJACC Heart Failure · 2026
16. Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCMCirculation · 2026
17. Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CMJournal of the American College of Cardiology · 2025
18. Diagnostic Performance of Cardiac and Whole-Body 124i-Evuzamitide (At-01) Pet/Mri in Systemic AmyloidosisJournal of the American College of Cardiology · 2025
19. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet · 2020
20. The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyJournal of Cardiac Failure · 2026
21. INSIGHT ModelJACC Advances · 2026
22. Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCMEuropean Journal of Heart Failure · 2026
23. Health Care Resource Utilization in Transthyretin Amyloid Cardiomyopathy Compared With Non‐amyloid Heart Failure and the General PopulationJournal of the American Heart Association · 2026
24. Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic CardiomyopathyCirculation · 2020
25. Effects of Acoramidis on Kidney Function in Transthyretin Amyloid CardiomyopathyCirculation Heart Failure · 2026
26. Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (Redwood-HCM Cohort 4)Journal of the American College of Cardiology · 2023
27. Natural Language Processing Framework in Early Detection of AmyloidosisJACC Advances · 2026
28. Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin AmyloidosisJACC CardioOncology · 2026
29. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2025
30. Aficamten in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2025
31. Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersenEuropean Journal of Heart Failure · 2026
32. Outpatient worsening heart failure in transthyretin amyloid cardiomyopathy: Findings from ATTRibute-CMEuropean Journal of Heart Failure · 2026
33. Predictors of Long-Term Outcomes in Hypertrophic CardiomyopathyJAMA · 2026
34. Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen ConsumptionJAMA Cardiology · 2023
35. Biomarkers as Clinical Endpoints in Hypertrophic Cardiomyopathy Clinical TrialsCurrent Heart Failure Reports · 2026
36. Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter StudyJournal of Cardiac Failure · 2026
37. Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term studyEuropean Heart Journal · 2025
38. Current Standards and Perspectives in Proteomics for Cardiac AmyloidosisAnalytical Chemistry · 2026
39. Heart Failure in Hypertrophic CardiomyopathyCardiac failure review · 2026
40. Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: Observations from ATTRibute-CMEuropean Journal of Heart Failure · 2026
41. Efficacy and Safety of Direct‐Acting Oral Anticoagulants in Atrial Fibrillation With Hypertrophic CardiomyopathyJournal of the American Heart Association · 2026
42. Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CMFuture Cardiology · 2026
43. Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathyESC Heart Failure · 2026
44. Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023JACC Advances · 2026
45. Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort StudyJournal of the American Heart Association · 2025
46. Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid CardiomyopathyJAMA Cardiology · 2025
47. Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCMCirculation Heart Failure · 2025
48. Emerging Pharmacological and Invasive Therapies for Hypertrophic Cardiomyopathy with Obstructive PhysiologyCardiac failure review · 2025
49. Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic CardiomyopathySHILAP Revista de lepidopterología · 2025
50. Efficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: Systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trialsProgress in Cardiovascular Diseases · 2025